序号 |
标题 |
次数 |
作者 |
发布时间 |
80776 |
DOTA-ZHER2:2891-Affibody |
146 |
wyh |
2024-11-28 |
80777 |
CAS:872469-60-8 大环化合物 |
75 |
zyl |
2024-11-28 |
80778 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)共轭GnRH肽 |
79 |
kx |
2024-11-28 |
80779 |
3,6-二取代苯基-1,4-二氢-S-四嗪-1,4-二甲酸甲酯化合物 |
79 |
WYQ |
2024-11-28 |
80780 |
3-氧代-5-取代芳基异唑[3,4-e]并-1,2,3,4-四嗪衍生物 |
75 |
WYQ |
2024-11-28 |
80781 |
cas:619300-53-7 DOTA-NOC;DOTA-Nal3-octreotide |
83 |
zcy |
2024-11-28 |
80782 |
CAS:157599-02-5 1,4,7,10-四(氨基羰甲基)-1,4,7,10-四氮杂环十二烷 |
78 |
zyl |
2024-11-28 |
80783 |
DOTA-peptide-(GGGF)-m170的结构组成 |
134 |
wyh |
2024-11-28 |
80784 |
DOTA-3P-RGD ,双功能螯合剂DOTA偶联环肽RGD二聚体 |
196 |
kx |
2024-11-28 |
80785 |
CAS:913542-71-9 DOTA di(tBu)ester |
82 |
zyl |
2024-11-28 |
80786 |
cas: 1192362-32-5 DOTA-LM3 |
99 |
zcy |
2024-11-28 |
80787 |
DOPE-PEG-DOTA 磷脂-聚乙二醇-大环配体 |
74 |
zyl |
2024-11-28 |
80788 |
DOTA-GX1 , 大环螯合剂DOTA缀合GX1肽 |
86 |
kx |
2024-11-28 |
80789 |
甲氧基DOTA;MeO-DOTA |
205 |
wyh |
2024-11-28 |
80790 |
cas:865470-67-3 DOTA-Thiol |
111 |
zcy |
2024-11-28 |
80791 |
3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-烷基酮 |
81 |
WYQ |
2024-11-28 |
80792 |
DOTA-tris(acid)-amido-dPEG-TFP ester |
93 |
zyl |
2024-11-28 |
80793 |
DOTA-赖氨酸(DOTA-L) |
115 |
kx |
2024-11-28 |
80794 |
p-NH2-benzyl-NOTA; p-NH2-苄基-NOTA缀合物 |
84 |
wyh |
2024-11-28 |
80795 |
3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-甲酸酯 |
64 |
WYQ |
2024-11-28 |
80796 |
cas:1908409-18-6 DOTA Zoledronate DOTA唑来膦酸盐 |
69 |
zcy |
2024-11-28 |
80797 |
CAS:177943-88-3 DOTATATE |
76 |
zyl |
2024-11-28 |
80798 |
钆-四氮杂环十二烷-四乙酸 , LPS+Gd-DOTA |
97 |
kx |
2024-11-28 |
80799 |
N-取代苯基-3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-甲酰胺 |
147 |
WYQ |
2024-11-28 |
80800 |
DOTA-RM2;胃泌素释放肽受体的示踪剂 |
106 |
wyh |
2024-11-28 |
80801 |
DOTA-(t-butyl)3-PEG5-azide(大环化合物) |
92 |
zcy |
2024-11-28 |
80802 |
Tm-Maleimido-DOTA cas1552305-24-4 双功能螯合剂 |
78 |
zyl |
2024-11-28 |
80803 |
DOTA-tris(OPp酯)缀合物 , DOTA-tris(tBuester) |
90 |
kx |
2024-11-28 |
80804 |
4-乙氧羰基-1,7-二氢-1-取代苯基-5-(未)取代吡唑啉[5,1-d][1,2,3,5]四嗪-7-酮衍生物 |
70 |
WYQ |
2024-11-28 |
80805 |
1-取代-3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪中N1位亚甲基(CH2) |
94 |
WYQ |
2024-11-28 |
80806 |
DOTA-AMBF3-PEG2-LLP2A;DOTA偶联跨膜蛋白极晚期抗原4 (VLA-4)的肽LLP2A |
156 |
wyh |
2024-11-28 |
80807 |
1-烷基-3-苯基-6-甲基-1,6-二氢-1,2,4,5-四嗪构象研究 |
92 |
WYQ |
2024-11-28 |
80808 |
DOTA-MUT-DS ,环状2-螺旋小蛋白偶联大环DOTA |
138 |
kx |
2024-11-28 |
80809 |
cas:2353410-19-0 Bromoacetamido-PEG5-DOTA 溴乙酰氨基-五聚乙二醇-DOTA |
138 |
zcy |
2024-11-28 |
80810 |
DOTA单酰胺螯合物偶联CLT1肽 , CLT1-dL-(Gd-DOTA) |
86 |
kx |
2024-11-28 |
80811 |
3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-烷基酮 |
73 |
WYQ |
2024-11-28 |
80812 |
3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-甲酸酯 |
81 |
WYQ |
2024-11-28 |
80813 |
DOTA修饰的声敏脂质体(GdSL ) , DOTA-GdSL |
158 |
kx |
2024-11-28 |
80814 |
1189194-65-7,DOTA-CH2-Alkynyl (TFA salt) |
81 |
zcy |
2024-11-28 |
80815 |
N-取代苯基-3-芳基-6-甲基-1,6-二氢-1,2,4,5-四嗪-1-甲酰胺 |
92 |
WYQ |
2024-11-28 |
80816 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸的酯化前体(DOTA18) |
83 |
kx |
2024-11-28 |
80817 |
1610950-41-8,DOTA-甲基四嗪 |
96 |
zcy |
2024-11-28 |
80818 |
204318-14-9,Edotreotide,奥曲肽的多肽,DOTA大环化合物 |
86 |
zcy |
2024-11-28 |
80819 |
DOTA缀合的9聚体高亲和力uPAR结合肽 , DOTA-AE105 |
103 |
kx |
2024-11-28 |
80820 |
环糊精金属有机框架/海藻酸钙复合材料 γ-CD-MOF-SH/CA |
96 |
h |
2024-11-28 |